Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Liabilities (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Total Liabilities for 10 consecutive years, with $344.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 27.46% to $344.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $344.0 million through Dec 2025, up 27.46% year-over-year, with the annual reading at $344.0 million for FY2025, 27.46% up from the prior year.
  • Total Liabilities for Q4 2025 was $344.0 million at Akebia Therapeutics, up from $322.6 million in the prior quarter.
  • The five-year high for Total Liabilities was $519.2 million in Q1 2022, with the low at $252.7 million in Q1 2024.
  • Average Total Liabilities over 5 years is $349.0 million, with a median of $319.5 million recorded in 2025.
  • The sharpest move saw Total Liabilities increased 29.86% in 2021, then crashed 42.21% in 2023.
  • Over 5 years, Total Liabilities stood at $455.3 million in 2021, then fell by 22.95% to $350.8 million in 2022, then dropped by 22.39% to $272.3 million in 2023, then fell by 0.89% to $269.9 million in 2024, then increased by 27.46% to $344.0 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $344.0 million, $322.6 million, and $316.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.